WO2008111632A1 - Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative - Google Patents
Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative Download PDFInfo
- Publication number
- WO2008111632A1 WO2008111632A1 PCT/JP2008/054568 JP2008054568W WO2008111632A1 WO 2008111632 A1 WO2008111632 A1 WO 2008111632A1 JP 2008054568 W JP2008054568 W JP 2008054568W WO 2008111632 A1 WO2008111632 A1 WO 2008111632A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor agonist
- glucocorticoid receptor
- trimethyl
- phenyl
- represent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
Abstract
Disclosed is a glucocorticoid receptor agonist composed of a 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative. Also disclosed is a novel pharmacological activity of the agonist. Specifically disclosed is a glucocorticoid receptor agonist composed of a compound represented by the formula (1) below or a salt thereof. [In the formulae below, R1 represents a group represented by the general formula (2a), (3a), (4a) or (5a); R2 and R3 may be the same or different and represent a hydrogen atom, a halogen atom, a lower alkyl group or the like; R4 represents a lower alkyl group; R5, R6, R7 and R8 represent a halogen atom, a lower alkyl group, a lower alkenyl group, a lower alkoxy group or the like; and m, n, p and q represent 0, 1 or 2.]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-063010 | 2007-03-13 | ||
JP2007063010 | 2007-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008111632A1 true WO2008111632A1 (en) | 2008-09-18 |
Family
ID=39759563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/054568 WO2008111632A1 (en) | 2007-03-13 | 2008-03-13 | Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2008255112A (en) |
WO (1) | WO2008111632A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2085389A1 (en) * | 2006-11-14 | 2009-08-05 | Santen Pharmaceutical Co., Ltd | Novel 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents |
WO2009139361A1 (en) * | 2008-05-12 | 2009-11-19 | 参天製薬株式会社 | Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative having substituted oxy group |
WO2010029986A1 (en) * | 2008-09-12 | 2010-03-18 | 参天製薬株式会社 | Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group having sulfonic acid ester structure introduced therein as substituent |
US8017775B2 (en) | 2005-09-14 | 2011-09-13 | Santen Pharmaceutical Co., Ltd. | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity |
US8193187B2 (en) | 2007-05-29 | 2012-06-05 | Santen Pharmaceutical Co., Ltd. | 1,2,3,4-tetrahydroquinoxaline compound with a phenyl group substituent having a sulfonic acid ester structure or a sulfonic acid amide structure introduced therein and having glucocorticoid receptor-binding activity |
WO2013108921A1 (en) * | 2012-01-20 | 2013-07-25 | 参天製薬株式会社 | Industrial process for preparation of 1,2-dihydroquinoline derivative or a salt thereof, and intermediate for preparation thereof |
US8551991B2 (en) | 2006-03-14 | 2013-10-08 | Santen Pharmaceutical Co., Ltd. | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity |
WO2018230713A1 (en) | 2017-06-16 | 2018-12-20 | 学校法人同志社 | Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent |
US11433090B2 (en) | 2017-06-16 | 2022-09-06 | The Doshisha | mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10510840A (en) * | 1994-12-22 | 1998-10-20 | リガンド・ファーマシューティカルズ・インコーポレイテッド | Steroid receptor modulator compounds and methods |
JP2006504678A (en) * | 2002-08-21 | 2006-02-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Glucocorticoid mimetics, process for producing the same, pharmaceutical composition thereof, and use thereof |
WO2006019716A1 (en) * | 2004-07-14 | 2006-02-23 | Ligand Pharmaceuticals, Inc. | Intracellular receptor modulator compounds and methods |
WO2007032556A1 (en) * | 2005-09-14 | 2007-03-22 | Santen Pharmaceutical Co., Ltd. | Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity |
-
2008
- 2008-03-13 JP JP2008063419A patent/JP2008255112A/en not_active Withdrawn
- 2008-03-13 WO PCT/JP2008/054568 patent/WO2008111632A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10510840A (en) * | 1994-12-22 | 1998-10-20 | リガンド・ファーマシューティカルズ・インコーポレイテッド | Steroid receptor modulator compounds and methods |
JP2006504678A (en) * | 2002-08-21 | 2006-02-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Glucocorticoid mimetics, process for producing the same, pharmaceutical composition thereof, and use thereof |
WO2006019716A1 (en) * | 2004-07-14 | 2006-02-23 | Ligand Pharmaceuticals, Inc. | Intracellular receptor modulator compounds and methods |
WO2007032556A1 (en) * | 2005-09-14 | 2007-03-22 | Santen Pharmaceutical Co., Ltd. | Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8420635B2 (en) | 2005-09-14 | 2013-04-16 | Santen Pharmaceutical Co., Ltd. | Method for preventing or treating a glucocorticoid receptor-related disease |
US8017775B2 (en) | 2005-09-14 | 2011-09-13 | Santen Pharmaceutical Co., Ltd. | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity |
US8551991B2 (en) | 2006-03-14 | 2013-10-08 | Santen Pharmaceutical Co., Ltd. | 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity |
US8975256B2 (en) | 2006-03-14 | 2015-03-10 | Santen Pharmaceutical Co., Ltd. | 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity |
US8008496B2 (en) | 2006-11-14 | 2011-08-30 | Santen Pharmaceutical Co., Ltd. | 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents |
EP2085387A4 (en) * | 2006-11-14 | 2010-12-15 | Santen Pharmaceutical Co Ltd | Novel 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents |
EP2085389A4 (en) * | 2006-11-14 | 2010-12-15 | Santen Pharmaceutical Co Ltd | Novel 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents |
EP2085388A4 (en) * | 2006-11-14 | 2010-12-15 | Santen Pharmaceutical Co Ltd | Novel 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents |
US8580784B2 (en) | 2006-11-14 | 2013-11-12 | Santen Pharmaceutical Co., Ltd. | Method for treating a disease related to the glucocorticoid receptor |
US8008498B2 (en) | 2006-11-14 | 2011-08-30 | Santen Pharmaceutical Co., Ltd. | 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents |
US8008497B2 (en) | 2006-11-14 | 2011-08-30 | Santen Pharmaceutical Co., Ltd. | 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents |
EP2085387A1 (en) * | 2006-11-14 | 2009-08-05 | Santen Pharmaceutical Co., Ltd | Novel 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents |
EP2085389A1 (en) * | 2006-11-14 | 2009-08-05 | Santen Pharmaceutical Co., Ltd | Novel 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents |
EP2085388A1 (en) * | 2006-11-14 | 2009-08-05 | Santen Pharmaceutical Co., Ltd | Novel 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents |
US8563551B2 (en) | 2006-11-14 | 2013-10-22 | Santen Pharmaceutical Co., Ltd. | Method for preventing or treating a disease related to the glucocorticoid receptor |
US8440660B2 (en) | 2006-11-14 | 2013-05-14 | Santen Pharmaceutical Co., Ltd. | Method for treating a disease related to the glucocorticoid receptor |
US8569493B2 (en) | 2007-05-29 | 2013-10-29 | Santen Pharmaceutical Co., Ltd. | Method for treating a homeostasis-related disease or glaucoma by administering a 1,2,3,4-tetrahyroquinoxaline compound |
US8193187B2 (en) | 2007-05-29 | 2012-06-05 | Santen Pharmaceutical Co., Ltd. | 1,2,3,4-tetrahydroquinoxaline compound with a phenyl group substituent having a sulfonic acid ester structure or a sulfonic acid amide structure introduced therein and having glucocorticoid receptor-binding activity |
US8426406B2 (en) | 2008-05-12 | 2013-04-23 | Santen Pharmaceutical Co., Ltd. | Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group |
EA019091B1 (en) * | 2008-05-12 | 2014-01-30 | Сантен Фармасьютикал Ко., Лтд. | Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative having substituted oxy group |
WO2009139361A1 (en) * | 2008-05-12 | 2009-11-19 | 参天製薬株式会社 | Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative having substituted oxy group |
EA018420B1 (en) * | 2008-09-12 | 2013-07-30 | Сантен Фармасьютикал Ко., Лтд. | Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivatives containing phenyl group having sulfonic acid ester structure introduced therein as substituent |
WO2010029986A1 (en) * | 2008-09-12 | 2010-03-18 | 参天製薬株式会社 | Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group having sulfonic acid ester structure introduced therein as substituent |
US8664221B2 (en) | 2008-09-12 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Method for treating an inflammatory disease by administering a 1,2,3,4- tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituent |
JP2013166752A (en) * | 2012-01-20 | 2013-08-29 | Santen Pharmaceut Co Ltd | Industrial process for preparation of 1,2-dihydroquinoline derivative or salt thereof, and intermediate for preparation thereof |
WO2013108921A1 (en) * | 2012-01-20 | 2013-07-25 | 参天製薬株式会社 | Industrial process for preparation of 1,2-dihydroquinoline derivative or a salt thereof, and intermediate for preparation thereof |
CN104136432A (en) * | 2012-01-20 | 2014-11-05 | 参天制药株式会社 | Industrial process for preparation of 1,2-dihydroquinoline derivative or a salt thereof, and intermediate for preparation thereof |
WO2018230713A1 (en) | 2017-06-16 | 2018-12-20 | 学校法人同志社 | Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent |
US11433090B2 (en) | 2017-06-16 | 2022-09-06 | The Doshisha | mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2008255112A (en) | 2008-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008111632A1 (en) | Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative | |
WO2009035067A1 (en) | Glucocorticoid receptor agonists consisting of 1,3,3-tri- methyl-7-phenyl-3,4-dihydro-1h-quinoxalin-2-one derivatives | |
TW200606152A (en) | Piperidine compound and process for preparing the same | |
WO2008051533A3 (en) | Benzimidazole compounds | |
WO2009072621A1 (en) | Substituted dihydroazole compound and pest control agent | |
MX2009004920A (en) | Novel aminopyrimidine derivatives as plk1 inhibitors. | |
WO2008087933A1 (en) | NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON IϰB KINASE β | |
WO2009156861A8 (en) | Substituted pyrimidone derivatives | |
EP2085387A4 (en) | Novel 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents | |
WO2008140066A3 (en) | Pyridone derivatives as p38a mapk inhibitors | |
WO2008111239A1 (en) | Antistatic agent and use thereof | |
WO2009057784A1 (en) | Heterocyclic compound | |
WO2008111604A1 (en) | Novel pyrimidine compound having benzyl(heterocyclicmethyl)amine structure and pharmaceutical product containing the same | |
WO2008093674A1 (en) | Novel thiadiazole derivative having kinase inhibitory activity | |
EP1798227A4 (en) | Serotonin 5-ht3 receptor agonist | |
TW200726470A (en) | 6,7-unsaturated-7-carbamoylmorphinan derivatives | |
WO2005115984A3 (en) | Large conductance calcium-activitated k channel opener | |
WO2008136444A1 (en) | Fused heterocyclic derivative | |
MX2010008361A (en) | Substituted arylamide oxazepinopyrimidone derivatives. | |
WO2007147771A3 (en) | Tetralin and indane derivatives and uses thereof | |
ATE396183T1 (en) | CHROMEAND DERIVATIVES AND THEIR USE AS LIGANDS OF THE 5-HT RECEPTOR | |
WO2008114812A1 (en) | Jak inhibitor | |
MX2010012303A (en) | Glucocorticoid receptor agonist composed of 2,2,4-trimethyl-6-phe nyl-1,2-dihydroquinoline derivative having substituted oxy group. | |
WO2009063991A1 (en) | Pyridooxazepine derivative and use thereof | |
WO2008155670A3 (en) | Arylamide pyrimidone compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08721981 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08721981 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |